摘要
联合应用ＴＩＬ和ＩＬ－２治疗肾细胞癌１７例，检测了治疗前后外周血淋巴细胞（ＰＢＬ）对ｋ５６２、Ｒａｊｉ细胞的杀伤活性及ＣＤ_３、ＣＤ_４、ＣＤ_８水平，结果治疗前对Ｋ５６２、Ｒａｊｉ细胞杀伤活性分别为２８．２３±１４．１８％及２２．３９±８．８４％，而治疗后的杀伤活性分别为３６．１８±１３．０８％及２６．４７±５．２７％，治疗前后比较，ＰＢＬ对Ｋ５６２及Ｒａｊｉ细胞的杀伤活性均有显著提高（Ｐ＜０．０５）。治疗前后ＰＢＬ中的ＣＤ_３分别为５６．５８±４．０３％及５８．４３±３．４９％，ＣＤ_４分别为３９．８８±１．５１％及４１．１９±１．９９％，ＣＤ_８分别为３０．２０±１．５２％及３３．５４±３．３３％，治疗前后有显著性差异（Ｐ＜０．０５）。随访３～１５个月，平均９．７个月，１３例无转移者均无瘤存活，有转移的４例中完全缓解１例，部分缓解１例，死亡２例。提示联合应用ＴＩＬ和ＩＬ－２可以提高病人免疫力，在质和量两方面提高ＰＢＬ中的ＣＤ_３、ＣＤ_４和ＣＤ_８水平，近期疗效较好。
Combined use of tumor-infiltrating lymphocytes(TIL)and interleukin-2(IL-2)was carried out for the treatment of renal cell carcinoma in l7 cases. After the treatment,the activity of peripheral blood lymphocytes(PBL)against K562 cells and Raji cells were 36.18±13.08% and 26.47±5.27% respectively.The respective activity before treatment was 28.32±14.18% and 22.39±8.84%.The CD_3、CD_4 and CD_8 levels of PBL after the treatment were 58.43±3.49%,41.19±1.99% and 33.54 ±3.33 %respectively,being also significantly increased as compared to their pretreatment levels(P<0.05).The patients have been followed up for 3 to 15 months and those with no metastasis have been all alive.Of the 4 patients with metastatic tumor,1 has been completely recuperated,another partialy recuperated and the other 2 were already dead.The combined use of TIL and IL-2 would raise the CD_3,CD_4 and CD_8 level yielding a good therapeutic effect on renal cell carcinoma.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
1996年第5期279-281,共3页
Chinese Journal of Urology
